The CD83-targeted chimeric antigen receptor (CAR) T cell targeted therapy was proposed based on the report by Shrestha and colleagues that CD83 was a novel target against graft-versus-host disease in AML patients undergoing bone marrow hematopoietic stem cell transplantation [31]. The gene discussed is CD83; the disease is acute myeloid leukemia.